SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Momenta Pharmaceuticals Inc.
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
3027 64 0 MNTA
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2177Sorry Tuck, but I pasted only half of what I had intended. I was not trying to tBiotech Jim-2/16/2010
2176In as much as the study was a comparison of branded versus generic, I would certtuck-2/16/2010
2175Reference standard, from Table 1: Trademark: Lovenox@/Clexane@ (Aventis Pharma Biotech Jim-2/15/2010
2174Thanks . . . not much info on them, but from a PowerPoint presentation thtuck-2/15/2010
2173nytimes.com This article isn't related to (MNTA), but rather what appears tArthur Radley-2/15/2010
2172The company may be Techdow Pharmaceutical, a Chinese company.rkrw-2/15/2010
2171[Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, rtuck-2/15/2010
2170M118 . . . might be a few nuggets in this recent paper? The high bioavaituck-2/15/2010
2169[Cell surface heparan sulfate glycosaminoglycans versus metastasis] >>Inttuck-2/15/2010
2168Here's a link to the abstract of the paper co-authored with Dr. Woodcock, wituck-2/15/2010
2167Teva would be thrown out of GPhMA if they launched a Copaxone AG, so the M356 coDewDiligence_on_SI22/13/2010
2166It does speak to all the pharma-pharma mergers and the gigantic cost of developirkrw22/12/2010
2165Why would the CEO admit to the fact they aren't planning future development Arthur Radley-2/12/2010
2164CC SeekingAplah: Momenta Pharmaceuticals, Inc. (MNTA) Q4 2009 Earnings Call Tranmopgcw22/12/2010
2163In any case, it was addressed with the Copaxone deal. Not only that but Novartisrkrw-2/12/2010
2162<i>> I have to disagree with you. I think the hybrid formula stinks forDewDiligence_on_SI-2/12/2010
2161MNTA ‘ReadMeFirst’ updated: <i>transcript of 4Q09 CC); 2010-2011 news floDewDiligence_on_SI-2/12/2010
2160I have to disagree with you. I think the hybrid formula stinks for mnta and is arkrw12/12/2010
2159Oops—use this link instead: siliconinvestor.comDewDiligence_on_SI-2/12/2010
2158The ‘hybrid’ economic terms when SNY launches a Lovenox AG: siliconinvestor.comDewDiligence_on_SI-2/12/2010
2157MNTA 2010-2011 Possible/Probable News Flow (updated based on 4Q09 CC): siliconiDewDiligence_on_SI-2/11/2010
2156MNTA ‘ReadMeFirst’ updated: <i>liquidity and cash usage (based on 4Q09 reDewDiligence_on_SI-2/11/2010
2155FDA Clears Drug Chief of Conflict By ALICIA MUNDY WASHINGTON—The inspector gentnsaf-2/5/2010
2154<i>>I’m sorry you felt it necessary to be so condescending in your replDewDiligence_on_SI22/3/2010
2153The fact is it's been over 4.5 years since Momenta filed and for others quitrkrw22/3/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News